The biotechnology firm turned cutting-edge science into a best-selling product in two years. Robert Cyran explains how its valuation is less based on its Covid-19 vaccine than faith it can do this again repeatedly – and how competition might be a problem.
00:40
01:20
00:41
00:28
01:22
01:03
02:09
00:58
00:53
01:18
01:03
01:46
02:43
02:00
00:41
00:46
00:42
01:47
02:14
01:01
00:40
01:03
02:29
00:57
02:22
00:47
01:22
01:08
01:01
02:59
01:49
00:49
02:23
00:50
02:26
01:53
00:45
01:09
00:55
01:27
01:20
01:18
01:03
01:01
00:27
01:15
01:30
02:37
00:40
00:40
00:30
01:15
00:17
02:26
00:47
00:28
00:52
00:33
01:05
00:25
01:46
01:02
01:28
01:57
01:03
02:00
03:34
01:30
00:51
02:02
00:51
02:07
02:05
01:36
01:23
02:26
01:11
00:28
01:38
01:00
02:14
01:18
01:09
01:23
01:26
01:35
01:07
02:52
05:07
01:11
01:01
01:42
01:55
01:29
00:59
00:49
00:57
01:41
02:09
01:36